additional navigation

You are here:

Corporate Profile Folder

Download Corporate Profile Folder (.pdf, 3.6 MB)

Ongoing Trials

Indication: polycythemia vera
Name of study: PEGINVERA

  • Safety study of pegylated interferon alpha 2b to treat polycythemia vera (PEGINVERA).
  • The goal of this study is to identify the maximum tolerated dose (MTD) of the medication under investigation. Moreover, the safety and tolerability will be assessed and an exploratory analysis of efficacy and biomaker modulation will be performed.

  • Link to the PEGINVERA study on clinicaltrials.gov

Focus: Cardiology

A short term pharmacokinetic, pharmacodynamic and tolerability study to compare AOP200704 vs. esmolol.